Cargando…

Transplanting FVIII/ET3-secreting cells in fetal sheep increases FVIII levels long-term without inducing immunity or toxicity

Hemophilia A is the most common X-linked bleeding disorder affecting more than half-a-million individuals worldwide. Persons with severe hemophilia A have coagulation FVIII levels <1% and experience spontaneous debilitating and life-threatening bleeds. Advances in hemophilia A therapeutics have s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rodriguez, Martin, Trevisan, Brady, Ramamurthy, Ritu M., George, Sunil K., Diaz, Jonathan, Alexander, Jordan, Meares, Diane, Schwahn, Denise J., Quilici, David R., Figueroa, Jorge, Gautreaux, Michael, Farland, Andrew, Atala, Anthony, Doering, Christopher B., Spencer, H. Trent, Porada, Christopher D., Almeida-Porada, Graça
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349136/ https://www.ncbi.nlm.nih.gov/pubmed/37452013 http://dx.doi.org/10.1038/s41467-023-39986-1

Ejemplares similares

Defining the Optimal FVIII Transgene for Placental Cell-Based Gene Therapy to Treat Hemophilia A
por: El-Akabawy, Nadia, et al.
Publicado: (2020)

Effects of Shear Stress on Production of FVIII and vWF in a Cell-Based Therapeutic for Hemophilia A
por: Trevisan, Brady, et al.
Publicado: (2021)

Comparison of different gene addition strategies to modify placental derived-mesenchymal stromal cells to produce FVIII
por: Ramamurthy, Ritu M., et al.
Publicado: (2022)

Autologous bone marrow-derived MSCs engineered to express oFVIII-FLAG engraft in adult sheep and produce an effective increase in plasma FVIII levels
por: Trevisan, Brady, et al.
Publicado: (2022)

Investigating Optimal Autologous Cellular Platforms for Prenatal or Perinatal Factor VIII Delivery to Treat Hemophilia A
por: Stem, Christopher, et al.
Publicado: (2021)

The Immune Response to the fVIII Gene Therapy in Preclinical Models
por: Patel, Seema R., et al.
Publicado: (2020)

Native plasma-derived FVIII/VWF complex has lower sensitivity to FVIII inhibitors than the combination of isolated FVIII and VWF proteins. Impact on Bethesda assay titration of FVIII inhibitors
por: Bravo, M I, et al.
Publicado: (2014)

Effects of FVIII immunity on hepatocyte and hematopoietic stem cell–directed gene therapy of murine hemophilia A
por: Lytle, Allison M, et al.
Publicado: (2016)

Co-administration of FVIII with IVIG reduces immune response to FVIII in hemophilia A mice
por: Afraz, Sajjad, et al.
Publicado: (2022)

Intrinsic differences between FVIIIa mimetic bispecific antibodies and FVIII prevent assignment of FVIII‐equivalence
por: Leksa, Nina C., et al.
Publicado: (2019)

Organoids and microphysiological systems: Promising models for accelerating AAV gene therapy studies
por: Ramamurthy, Ritu Mahesh, et al.
Publicado: (2022)

Acquired Hemophilia A (FVIII Deficiency) Associated with Papillary Thyroid Cancer: Treatment with Recombinant Porcine FVIII
por: Nguyen, S., et al.
Publicado: (2019)

Modulating the microenvironment during FVIII uptake influences the nature of FVIII-peptides presented by antigen-presenting cells
por: Lubich, Christian, et al.
Publicado: (2022)

Development and Characterization of Recombinant Ovine Coagulation Factor VIII
por: Zakas, Philip M., et al.
Publicado: (2012)

In utero stem cell transplantation and gene therapy: rationale, history, and recent advances toward clinical application
por: Almeida-Porada, Graça, et al.
Publicado: (2016)

Utility of a high VWF:FVIII ratio in preventing FVIII accumulation: a study in VWF-deficient mice
por: Raquet, Elmar, et al.
Publicado: (2015)

Genetic variations in sites of affinity between FVIII and LRP1 are not associated with high FVIII levels in venous thromboembolism
por: Bittar, Luis F., et al.
Publicado: (2015)

Restoration of FVIII expression by targeted gene insertion in the FVIII locus in hemophilia A patient-derived iPSCs
por: Sung, Jin Jea, et al.
Publicado: (2019)

Therapeutic Mesenchymal Stromal Cells for Immunotherapy and for Gene and Drug Delivery
por: Almeida-Porada, Graça, et al.
Publicado: (2020)

Recombinant FVIII: the milestone of modern hemophilia treatment
por: Mannucci, Pier Mannuccio
Publicado: (2023)

In Vitro FVIII-Encoding Transgenic Mesenchymal Stem Cells Maintain Successful Coagulation in FVIII-Deficient Plasma Mimicking Hemophilia A
por: Hemşinlioğlu, Cansu, et al.
Publicado: (2023)

Occurrence of FVIII Inhibitors in Hemophilia A Patients Following an Institutional Switch to a Third Generation B-Domain-Deleted FVIII
por: Hooimeijer, Louise H, et al.
Publicado: (2023)

Hemophilia A: an ideal disease to correct in utero
por: Porada, Christopher D., et al.
Publicado: (2014)

Current Understanding of Inherited Modifiers of FVIII Pharmacokinetic Variation
por: Swystun, Laura L, et al.
Publicado: (2023)

Markedly Reduced FVIII Recovery Associated with Anti-FVIII Peg Antibodies after BNT162b2 Sars-Cov-2 Vaccination
por: Valsecchi, Carla, et al.
Publicado: (2022)

Reduced FVIII recovery associated with anti-FVIII PEG antibodies after BNT162b2 SARS-CoV-2 vaccination
por: Valsecchi, Carla, et al.
Publicado: (2022)

The dataset from administration of single or combined immunomodulation agents to modulate anti-FVIII antibody responses in FVIII plasmid or protein primed hemophilia A mice
por: Liu, Chao Lien, et al.
Publicado: (2016)

Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias
por: Mancuso, Maria Elisa, et al.
Publicado: (2014)

Immune Responses to Plasma-Derived Versus Recombinant FVIII Products
por: Peyvandi, Flora, et al.
Publicado: (2021)

Plasma‐derived FVIII/VWF complex shows higher protection against inhibitors than isolated FVIII after infusion in haemophilic patients: A translational study
por: Bravo, Maria Isabel, et al.
Publicado: (2022)

Phenotypes of Allo- and Autoimmune Antibody Responses to FVIII Characterized by Surface Plasmon Resonance
por: Lewis, Kenneth B., et al.
Publicado: (2013)

Boosting Hematopoietic Engraftment after in Utero Transplantation through Vascular Niche Manipulation
por: Mokhtari, Saloomeh, et al.
Publicado: (2016)

Real-Life Pharmacokinetics of rFVIII-Fc and rFIX-Fc
por: Traets, Marissa J.M., et al.
Publicado: (2020)

FVIII inhibitors display FV‐neutralizing activity in the prothrombin time assay
por: Arsiccio, Andrea, et al.
Publicado: (2021)

Comparative evaluation of the safety and efficacy of recombinant FVIII in severe hemophilia A patients
por: Abolghasemi, Hassan, et al.
Publicado: (2018)

Molecular Aggregation of Marketed Recombinant FVIII Products: Biochemical Evidence and Functional Effects
por: De Cristofaro, Raimondo, et al.
Publicado: (2019)

Outcome of Clinical Trials with New Extended Half-Life FVIII/IX Concentrates
por: Mancuso, Maria Elisa, et al.
Publicado: (2017)

Experimental validation of a predicted microRNA within human FVIII gene
por: Jalali-Qomi, Shahabeddin, et al.
Publicado: (2021)

Recurrent vital thrombotic events in a young man with FVIII gene duplication
por: Wang, Ling-Li, et al.
Publicado: (2021)

Nonneutralizing FVIII-specific antibody signatures in patients with hemophilia A and in healthy donors
por: Schweiger, Helmut, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_37eek4v8p7bk0cs9skmtqqm3nc